Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it expects to receive CNY 48 million in funding from Kunming Longjin Pharmaceutical Co., Ltd.
September 31, 2020
Share
Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it will receive CNY 48 million in an equity round of funding on September 1, 2020. The transaction will include participation from returning investor Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) to retain its 100% stake in the company. Post completion of the transaction, the capital of the company will increase from CNY 25.5 million to CNY 73.5 million. The transaction has been approved by the board of directors of Kunming Longjin Pharmaceutical Co., Ltd. in the nineteenth meeting of the fourth board of directors.
Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.
Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it expects to receive CNY 48 million in funding from Kunming Longjin Pharmaceutical Co., Ltd.
KUNMING LONGJIN PHARMACEUTICAL CO., LTD. 
